Carvedilol clinical trials
Carvedilol is named as an intervention in 19 current clinical trials in our India, South Korea, Egypt, Denmark, Mexico, China, France, Brazil and Taiwan registers. 11 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Institute of Liver and Biliary Sciences, India (4). The most-studied condition is Cirrhosis. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Carvedilol is approved
All regulators →Of the three regulators tracked here, the first to approve Carvedilol was Canada, on 27 Feb 1995. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Carvedilol
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Carvedilol works
All drug targets →- Adrenergic receptor beta antagonist AntagonistTarget: Adrenergic receptor beta✓ In ChEMBL and the Guide to Pharmacology
- Adrenergic receptor alpha-1 antagonist AntagonistTarget: Adrenergic receptor alpha-1✓ In ChEMBL and the Guide to Pharmacology
- TachycardiaPhase 3
- Atrial fibrillationPhase 3
- CardiotoxicityPhase 3
- Esophageal varicesPhase 3
- Essential hypertensionPhase 3
- Kidney failurePhase 3
- Left ventricular hypertrophyPhase 3
- Portal hypertensionPhase 3
- Tricuspid valve insufficiencyPhase 3
- SeizurePhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL723, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 551, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Carvedilol
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Carvedilol
- ATC code
- C07AG02
- ChEMBL
- CHEMBL723
- DrugBank
- DB01136
- PubChem CID
- 2585
- CAS number
- 72956-09-3
- FDA UNII
- 0K47UL67F2
- Wikidata
- Q412534
- Wikipedia
- Carvedilol
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Carvedilol
19 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Carvedilol in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Carvedilol. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
2025-521780-12-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Ongoing | Andrea Di Marco | Spain |
Carvedilol across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
7 single-substance products containing Carvedilol on the HPRA medicines list.
- Carvedilol Krka 12.5 mg TabletsKRKA, d.d., Novo mesto · PA1347/037/003 · Marketed
- Carvedilol Krka 25 mg TabletsKRKA, d.d., Novo mesto · PA1347/037/004 · Marketed
- Carvedilol Krka 3.125 mg TabletsKRKA, d.d., Novo mesto · PA1347/037/001 · Marketed
- Carvedilol Krka 6.25 mg tabletsKRKA, d.d., Novo mesto · PA1347/037/002 · Marketed
- Eucardic 12.5 mg TabletsCHEPLAPHARM Arzneimittel GmbH · PA2239/001/002 · Marketed
Supply shortages
No entry for Carvedilol in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Carvedilol
29 conditionsAll 29 conditions
| Condition (as registered) | Trials |
|---|---|
| Cirrhosis | 4 |
| Liver Cirrhosis | 2 |
| Cirrhotic Cardiomyopathy | 2 |
| Cardiotoxicity | 2 |
| Esophageal Varices | 2 |
| Hepatocellular Carcinoma | 1 |
| Decompensated Cirrhosis | 1 |
| Cirrhosis, Liver | 1 |
| Left Ventricular Diastolic Dysfunction | 1 |
| Empagliflozin | 1 |
| Cardiometabolic Risk Factors | 1 |
| Rebleeding of Portal Hypertension in Liver Cirrhosis | 1 |
| Propranolol | 1 |
| Carvedilol | 1 |
| Portal Hypertension Related to Cirrhosis | 1 |
| Chronic Heart Failure | 1 |
| Acute Myocardial Infarction | 1 |
| Non-ST Elevation Myocardial Infarction (nSTEMI) | 1 |
| ST Elevation Myocardial Infarction | 1 |
| Cancer | 1 |
| HER2/Neu Positive | 1 |
| Metastatic Malignant Neoplasm in the Brain | 1 |
| Recurrent Breast Carcinoma | 1 |
| End-Stage Kidney Disease | 1 |
| End-Stage Renal Disease | 1 |
| Decompensated Cirrhosis of Liver | 1 |
| Chronic Coronary Syndrome | 1 |
| Hepatocellular Carcinoma (HCC) | 1 |
| TBI Traumatic Brain Injury | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Carvedilol trials
How many clinical trials are testing Carvedilol?
19 current trials in our India, South Korea, Egypt, Denmark, Mexico, China, France, Brazil and Taiwan registers name Carvedilol (also registered as CARVEDILOL ARROW 6) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Carvedilol trials recruiting patients?
Yes. 11 of the 19 trials are recruiting: 4 with sites in India, 1 with sites in South Korea, 3 with sites in Egypt, 2 with sites in Mexico, 1 with sites in France and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Carvedilol clinical trials?
Institute of Liver and Biliary Sciences, India (4), Post Graduate Institute of Medical Education and Research, Chandigarh (2), Xijing Hospital (1) and University Hospital, Clermont-Ferrand (1), among 15 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Carvedilol licensed in Ireland?
Yes. The HPRA medicines list includes 7 single-substance products containing Carvedilol, for example Carvedilol Krka 12.5 mg Tablets (KRKA, d.d., Novo mesto). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Carvedilol shortage?
Not in the lists we track: Carvedilol has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Carvedilol works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Carvedilol works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Carvedilol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.